Uveitic Macular Edema: Assessing and Treating a Complex Condition

Author(s)/Faculty: Pauline T. Merrill, MD, FASRS; Christopher R. Henry, MD; Ashvini K. Reddy, MD
Release Date: 8/19/2022Expiration Date: 8/18/2023
Credit Type: CMENumber of Credits: 1.25
Content Type: LectureProvider:
Development of uveitic macular edema (UME) in patients with uveitis is associated with considerable clinical and economic burden, and it is the most common cause of vision loss, regardless of the anatomical type of uveitis present. The lack of treatment guidelines for the management of UME, along with no FDA-approved therapies, has further added to the challenge of care for these patients. Systemic, topical, or intravitreal corticosteroids have been utilized as first-line therapies, depending on the etiology and severity. In patients who are non-responsive to steroids, immunosuppressants, biological therapies, and vitreoretinal surgery have been used. The FDA recently approved the first therapy for the treatment of UME providing an innovative treatment option for these patients. In this continuing medical education activity, experts in the field discuss the complex etiologies of UME, evaluate modalities that effectively aid in the differential diagnosis of UME, and review new evidence regarding the safety and efficacy of conventional, new, and emerging treatment options for patients with UME.